Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sangamo Therapeutics (NQ: SGMO ) 0.5600 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,326,699 Open 0.5600 Bid (Size) 0.4825 (25) Ask (Size) 0.4900 (62) Prev. Close 0.5600 Today's Range 0.5600 - 0.5600 52wk Range 0.2911 - 1.480 Shares Outstanding 145,337,046 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today? July 24, 2024 Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results. Via InvestorPlace Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings July 24, 2024 Via Benzinga Exposures Fossil Fuels Performance YTD +0.67% +0.67% 1 Month +19.20% +19.20% 3 Month +13.59% +13.59% 6 Month +26.75% +26.75% 1 Year -58.52% -58.52% More News Read More Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session July 24, 2024 Via Benzinga 4 Analysts Assess Sangamo Therapeutics: What You Need To Know March 13, 2024 Via Benzinga Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results July 24, 2024 Via Benzinga Topics Stocks Exposures US Equities Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study July 24, 2024 Via Benzinga Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate July 24, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA July 11, 2024 Via AB Newswire Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know May 15, 2024 Via Benzinga SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results May 09, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing May 09, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast May 02, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) April 22, 2024 From Sangamo Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Friday's Intraday Session March 22, 2024 Via Benzinga Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering March 22, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform March 19, 2024 Via Benzinga Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results March 13, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs March 13, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Earnings Scheduled For March 13, 2024 March 13, 2024 Via Benzinga Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast March 12, 2024 From Sangamo Therapeutics, Inc. Via Business Wire 12 Health Care Stocks Moving In Monday's Intraday Session February 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session February 12, 2024 Via Benzinga Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease February 12, 2024 From Sangamo Therapeutics, Inc. Via Business Wire Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket February 06, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
